Compare AFYA & CRVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AFYA | CRVS |
|---|---|---|
| Founded | 1999 | 2014 |
| Country | Brazil | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.0B |
| IPO Year | 2019 | 2016 |
| Metric | AFYA | CRVS |
|---|---|---|
| Price | $14.50 | $13.05 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 6 |
| Target Price | $17.00 | ★ $30.17 |
| AVG Volume (30 Days) | 90.3K | ★ 1.2M |
| Earning Date | 05-08-2026 | 05-07-2026 |
| Dividend Yield | ★ 4.90% | N/A |
| EPS Growth | N/A | ★ 48.04 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $10.43 | N/A |
| Revenue Next Year | $7.15 | N/A |
| P/E Ratio | $9.30 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $13.00 | $3.71 |
| 52 Week High | $18.16 | $26.95 |
| Indicator | AFYA | CRVS |
|---|---|---|
| Relative Strength Index (RSI) | 57.35 | 56.38 |
| Support Level | $14.24 | $12.95 |
| Resistance Level | $14.77 | $14.00 |
| Average True Range (ATR) | 0.44 | 0.68 |
| MACD | 0.03 | 0.28 |
| Stochastic Oscillator | 88.06 | 96.12 |
Afya Ltd is a medical education group based in Brazil. Its education portfolio has several courses in addition to Medicine, such as Management, Dentistry, Law, Engineering, Nursing, Psychology, and Accounting Sciences, among others. It has three segments; Undergraduate, deriving key revenue provides educational services through undergraduate courses related to medical school, undergraduate health science and other ex-health undergraduate programs, Continuing Education provides medical education, specialization and graduate courses in medicine, delivered through digital and in-person content; and Medical practice solution provides clinical decision, clinical management and doctor-patient relationships for physicians and provide access, demand and efficiency for the healthcare players.
Corvus Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. It believes its proprietary product candidates have broad potential to address immune mediated diseases, inflammatory diseases and cancers. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The company operates in one primary business activity and operate as one reportable segment.